{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:34:07Z","timestamp":1790231647838,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.vph.2014.03.004","type":"journal-article","created":{"date-parts":[[2014,3,29]],"date-time":"2014-03-29T04:48:26Z","timestamp":1396068506000},"page":"94-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Risk prediction with proprotein convertase subtilisin\/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment"],"prefix":"10.1016","volume":"62","author":[{"given":"Christian","family":"Werner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vph.2014.03.004_bb0120","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"issue":"26","key":"10.1016\/j.vph.2014.03.004_bb0125","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMra1106700","article-title":"Proprotein convertases in health and disease","volume":"365","author":"Artenstein","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vph.2014.03.004_bb0130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nrendo.2012.254","article-title":"Cardiovascular endocrinology in 2012: PCSK9\u2014an exciting target for reducing LDL-cholesterol levels","volume":"9","author":"Betteridge","year":"2013","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"10.1016\/j.vph.2014.03.004_bb0135","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.vph.2014.03.004_bb0210","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting the proprotein convertase subtilisin\/kexin type 9 (PCSK9) for the treatment of dyslipidemia and atherosclerosis","volume":"62","author":"Urban","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2014.03.004_bb0215","author":"U.S. National Institutes of Health"},{"issue":"5","key":"10.1016\/j.vph.2014.03.004_bb0220","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jacc.2013.09.048","article-title":"AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of NCEP-ATP III LDL-C goals among high risk patients: an analysis from the LAPLACE-TIMI 57 trial","volume":"63","author":"Desai","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.vph.2014.03.004_bb0155","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.vph.2014.03.004_bb0225","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.vph.2014.03.004_bb0165","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"issue":"9836","key":"10.1016\/j.vph.2014.03.004_bb0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vph.2014.03.004_bb0175","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.vph.2014.03.004_bb0180","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vph.2014.03.004_bb0185","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/ATVBAHA.108.181586","article-title":"Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia","volume":"29","author":"Le May","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.vph.2014.03.004_bb0190","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9","volume":"49","author":"Careskey","year":"2008","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.vph.2014.03.004_bb0195","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.atherosclerosis.2010.05.027","article-title":"Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients","volume":"212","author":"Costet","year":"2010","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.vph.2014.03.004_bb0200","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1194\/jlr.M008144","article-title":"High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol","volume":"51","author":"Welder","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vph.2014.03.004_bb0205","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"2013","author":"Stone","year":"2013","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.vph.2014.03.004_bb0010","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.vph.2014.03.004_bb0015","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jacc.2011.12.035","volume":"59","author":"Mora","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.vph.2014.03.004_bb0020","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.111.088591","article-title":"Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the treating to new targets (TNT) study","volume":"125","author":"Mora","year":"2012","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.vph.2014.03.004_bb0230","first-page":"S4","article-title":"Executive summary: standards of medical care in diabetes\u20142011","volume":"34","author":"American Diabetes Association","year":"2011","journal-title":"Diabetes Care"},{"issue":"16","key":"10.1016\/j.vph.2014.03.004_bb0030","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"i-xii","key":"10.1016\/j.vph.2014.03.004_bb0235","first-page":"1","article-title":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation","volume":"894","author":"World Health Organization","year":"2000","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"22","key":"10.1016\/j.vph.2014.03.004_bb0240","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1161\/CIRCULATIONAHA.107.187397","article-title":"Universal definition of myocardial infarction","volume":"116","author":"Thygesen","year":"2007","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.vph.2014.03.004_bb0045","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.jacc.2013.01.014","volume":"61","author":"Anderson","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.vph.2014.03.004_bb0050","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa043814","article-title":"Circulating endothelial progenitor cells and cardiovascular outcomes","volume":"353","author":"Werner","year":"2005","journal-title":"N Engl J Med"},{"issue":"48","key":"10.1016\/j.vph.2014.03.004_bb0055","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.vph.2014.03.004_bb0060","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1194\/jlr.M013664","article-title":"Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9","volume":"52","author":"Ason","year":"2011","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.vph.2014.03.004_bb0065","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.vph.2014.03.004_bb0070","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1161\/ATVBAHA.112.250043","article-title":"Proprotein convertase subtilisin\/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor","volume":"32","author":"Sun","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"20","key":"10.1016\/j.vph.2014.03.004_bb0075","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jacc.2011.12.043","article-title":"Plasma PCSK9 levels and clinical outcomes in the TNT (treating to new targets) trial: a nested case\u2013control study","volume":"59","author":"Huijgen","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.vph.2014.03.004_bb0080","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1161\/ATVBAHA.110.209007","article-title":"Beyond LDL cholesterol, a new role for PCSK9","volume":"30","author":"Akram","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.vph.2014.03.004_bb0085","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/MOL.0b013e32834622b5","article-title":"Unexpected roles for PCSK9 in lipid metabolism","volume":"22","author":"Soutar","year":"2011","journal-title":"Curr Opin Lipidol"},{"issue":"12","key":"10.1016\/j.vph.2014.03.004_bb0090","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J Lipid Res"},{"issue":"9","key":"10.1016\/j.vph.2014.03.004_bb0095","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","article-title":"Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents","volume":"55","author":"Baass","year":"2009","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.vph.2014.03.004_bb0100","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.atherosclerosis.2010.09.027","article-title":"Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population","volume":"213","author":"Cui","year":"2010","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.vph.2014.03.004_bb0105","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.vph.2014.03.004_bb0110","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1463-1326.2010.01229.x","article-title":"Fenofibrate concomitantly decreases serum proprotein convertase subtilisin\/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients","volume":"12","author":"Chan","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.vph.2014.03.004_bb0115","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.febslet.2009.12.018","article-title":"PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities","volume":"584","author":"Mbikay","year":"2010","journal-title":"FEBS Lett"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189114000573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189114000573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T03:55:38Z","timestamp":1538711738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189114000573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1537189114000573"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2014.03.004","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk prediction with proprotein convertase subtilisin\/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2014.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2014.05.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}